This edition of the Drug Discovery TOE depicts trends across clinical pharmacogenomics exemplified with prospective innovations worldwide. Although still much research needs to be carried out to leverage genomic information in the development of more personalized and cost-effective strategies in drug discovery and development, the impact of clinical pharmacogenomics in precision medicine is decisive.
The corresponding patent scenario is depicted, along with the industry interactions.
The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.
The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: Software analytics, pharmacogenomics testing, clinical best practices, pharmacogenomic genes, adverse drug interactions, drug-related side-effects